Respiratory Inhalers Market Share

Global Respiratory Inhalers Market Overview

The Respiratory Inhalers Market size was valued at USD 29.8 billion in 2023 and is projected to grow from USD 31.17 Billion in 2024 to USD 50.7 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 4.6% during the forecast period (2024 - 2032). The increased prevalence of respiratory conditions including asthma, COPD, and cystic fibrosis, among others, is one of the market drivers for respiratory inhalers.

Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review

Respiratory Inhalers Market Trends

• Rising prevalence of respiratory disorders to propel market growth

Asthma, COPD, and cystic fibrosis are just a few of the respiratory ailments whose prevalence is on the rise and are significant market drivers for inhalers for the lungs. For instance, according to data from the World Health Organization (2022), the toll of asthma deaths in 2019 was 455,000, affecting around 262 million people. Additionally, the Burden of Disease Study (2019) found 212.3 million prevalent cases of COPD worldwide, resulting in 3.3 million deaths in the calendar year 2019. The prevalence of cystic fibrosis is steadily rising, along with that of asthma and COPD. According to information from the March of Dimes Organization (2019), there were between 70,000 and 100,000 cases of cystic fibrosis worldwide in 2019. Both men and women were affected at the same rate. Thus, this factor is driving the market CAGR.

Moreover, in the approaching years, it is anticipated that increased air pollution will also increase demand for respiratory inhalers. For instance, the Organization for Economic Co-operation and Development estimates that by 2050, worldwide emissions of greenhouse gases (GHs) could rise by nearly 50%, primarily due to a 70% increase in CO2 emissions connected to energy use. Additionally, it was noted that by 2050, the atmospheric concentration of GHGs might reach 685 parts per million (ppm) CO2-equivalents, which would cause average temperatures to rise by 3 to 6 degrees Celsius above pre-industrial levels. Therefore, when the amount of pollution in various nations throughout the world increased significantly, so did the number of patients with COPD and asthma.

However, due to their positive effects on patients, combination therapy for asthma are increasingly being used, which has increased demand for respiratory inhalers such dry powder inhalers and soft mist inhalers. One of the key factors fueling the growth of the respiratory inhaler device market is the fact that inhaler devices are increasingly one of the finest ways to administer combination medications. Thus, it is anticipated that this aspect will accelerate respiratory inhalers market revenue globally.

Respiratory Inhalers Market Segment Insights

Respiratory Inhalers Type Insights

The respiratory inhalers market segmentation has been segmented by type into Manually Operated and Digitally Operated. The wearable segment dominated the market growth in 2021 and is projected to be the faster-growing segment during the forecast period, 2024-2032. The main objective of manually operated inhaler equipment is to enhance medicine delivery to provide better management of respiratory disorders. The technique has a number of benefits, including a quick beginning of effect, the ability to administer medication in precise quantities, and systematic absorption.

Respiratory Inhalers Product Insights

The respiratory inhalers market segmentation, based on product is divided into Dry Powder Inhaler, Metered Dose Inhaler and Others. The dry powder inhaler segment dominated the respiratory inhalers market revenue in 2023 and is projected to be the faster-growing segment during the forecast period, 2024-2032. A dry powder inhaler (DPI) is a tool for inhaling dry powder medications into the lungs through the mouth. The most popular kinds of respiratory inhalers on the market are humidifiers and nebulizers. There are various kinds, such as pressurized metered-dosage inhalers (pMDIs), which utilize an aerosol formulation for delivery, and metered dose inhalers, which use a liquid formulation for administration.

Figure 2: Respiratory Inhalers Market by Product, 2023 & 2032 (USD Billion) 

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Respiratory Inhalers Application Insights

The respiratory inhalers market data has been segmented by application into Asthma, COPD and Other. The asthma segment dominated the market growth in 2021 and is projected to be the faster-growing segment during the forecast period, 2024-2032. Bronchodilators, which are administered via inhalers, are the most often prescribed drug for asthma. Over the projection period, it is also anticipated that increased awareness of asthma and its treatments will increase demand for respiratory inhalers.

Respiratory Inhalers End User Insights

The respiratory inhalers market data has been segmented by end user into Hospitals & Clinics and Respiratory Care Center. The hospitals & clinics segment dominated the market growth in 2021 and is projected to be the faster-growing segment during the forecast period, 2022-2030. physical

Respiratory Inhalers Regional Insights

By region, the study provides the market insights into North America, Europe, Asia-Pacific, and the Rest of the World. North America respiratory inhalers market accounted for USD 12.5 billion in 2021 and is expected to exhibit a 44.30% CAGR during the study period. This market is expanding as a result of factors like increased demand for soft mist and dry powder inhalers to treat asthma, as well as increased product introductions by major companies. The growth of the respiratory inhaler market is being driven by the rising use of metered dosage inhalers for the treatment of chronic obstructive pulmonary disease.

Further, the major countries studied in the market report are: The U.S., Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 3: RESPIRATORY INHALERS MARKET SHARE BY REGION 2023 (%)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Asia Pacific respiratory inhalers market accounts for the fastest growing market share. The increased use of combination therapies for respiratory devices and increasing investments by the major players in the development of sophisticated respiratory inhalers are some of the factors contributing to the growth of this market. Further, the China respiratory inhalers market held the largest market share, and the India respiratory inhalers market was the fastest-growing market in the region.

Europe respiratory inhalers market is expected to grow at a substantial CAGR from 2024 -2032 due to the rising rates of asthma and COPD. The demand for respiratory inhalers rises as the number of people with these diseases rises, fostering the development of this area. The availability of cutting-edge items in this region, together with the existence of significant industry players, also contribute to the market's expansion. Moreover, UK respiratory inhalers market held the largest market share, and the Germany respiratory inhalers market was the fastest-growing market in this region

Respiratory Inhalers Key Market Players & Competitive Insights

Major market players are spending a lot on R&D to increase their product lines, which will help the respiratory inhalers industry grow even more. Market participants are also taking various strategic initiatives to grow their worldwide footprint, including new product launches, contractual agreements, mergers and acquisitions, increased investments, market developments and collaboration with other organizations. Competitors in the industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market industry.

One of the primary business strategies manufacturers adopt in the respiratory inhalers industry to benefit clients and expand the sector is manufacturing locally to reduce operating costs. In recent years, respiratory inhalers industry has provided medicine with some of the most significant benefits. The respiratory inhalers market major player such as Teva Pharmaceutical Industries Ltd., AstraZeneca, PARI Medical Holding, Beximco Pharmaceuticals Ltd., OMRON Healthcare Europe, Boehringer Ingelheim GmbH, Merck & Co Inc., GlaxoSmithKline plc, Cipla Ltd and Koninklijke Philips N.V.

Israeli pharmaceutical corporation Teva Pharmaceutical Industries Ltd. is based in Tel Aviv. Generic medications are its main area of expertise, but it also has certain additional business interests in active pharmaceutical ingredients and, to a lesser extent, patented drugs. In October 2020, Teva Canada, a division of Teva Pharmaceutical Industries Ltd., announced that the manually controlled inhaler Aermony RespiClick is now available in Canada. The inhaler, which comes in an easy-to-use inhaler, is intended for the preventive maintenance treatment of steroid-responsive bronchial asthma in patients 12 years of age and older.

The Boehringer Ingelheim group was established in 1885 by Albert Boehringer in Ingelheim am Rhein, Germany. C.H. Boehringer Sohn AG & Co. KG is the organization's parent. One of the biggest pharmaceutical firms in the world—and the biggest private one—as of 2018 is Boehringer Ingelheim. In September 2019, Respimat Reusable, the first reusable soft mist inhaler from Boehringer Ingelheim, can hold up to six cartridges and further reduces carbon footprint by 71%.

Key companies in the respiratory inhalers market includes

• Teva Pharmaceutical Industries Ltd.


• AstraZeneca


• PARI Medical Holding


• Beximco Pharmaceuticals Ltd.


• OMRON Healthcare Europe


• Boehringer Ingelheim GmbH


• Merck & Co Inc.


• GlaxoSmithKline plc


• Cipla Ltd.


• Koninklijke Philips N.V

September 2020:Two digital maintenance inhalers for asthma sufferers, the AirDuo Digihaler and the ArmonAir Digihaler, have been made available by Teva Respiratory, LLC, a subsidiary of Teva Pharmaceutical Industries Ltd. in the United States.

January 2020:The pharmaceutical respiratory device from Senzer Pharmaceuticals will be used in Project TWENTY21, a medical cannabis registry in Europe, as a result of a partnership between Senzer Pharmaceuticals and Drug Science, a top independent scientific body on drugs in the U.K. that is in charge of Project TWENTY21.

Respiratory Inhalers Market Segmentation

Respiratory Inhalers Type Outlook (USD Billion, 2018-2032)

• Manually Operated


• Digitally Operated

Respiratory Inhalers Product Outlook (USD Billion, 2018-2032)

• Dry Powder Inhaler


• Metered Dose Inhaler


• Others

Respiratory Inhalers Application Outlook (USD Billion, 2018-2032)

• Asthma


• COPD


• Other

Respiratory Inhalers End User Outlook (USD Billion, 2018-2032)

• Hospitals & Clinics


• Respiratory Care Center

Respiratory Inhalers Regional Outlook (USD Billion, 2018-2032)

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe

• 
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America